Retractable Technologies(NYSEMKT) RVP

Retractable Technologies makes safety syringes and medical devices for hospitals and clinics. Its products help protect healthcare workers from accidental needle injuries. The company’s syringes and needles are used in everyday medical care and vaccinations.

Needles, Syringes, and More: What’s in the Box?

• Syringes (68.8% of sales in the first six months of 2025): Safety syringes with automatic needle retraction, used for injections and vaccinations.
• EasyPoint products (27.6%): Needles and blood collection holders designed for safer blood draws and injections.
• Other safety devices (3.6%): IV catheters, blood collection sets, and adapters for specialized medical uses.
• Patient Safe syringes: Syringes and caps that help prevent medication errors in hospitals.
• Allergy trays and accessories: Tools for allergy testing and small-volume injections in clinics.

Growth Spurts and Strategic Moves

• Expanded U.S. manufacturing in 2023-2025 to reduce reliance on Chinese imports.
• Entered a Technology Investment Agreement with the U.S. government in 2020, boosting domestic production capacity.
• Adapted equipment in 2025 to make more 0.5mL syringes in the U.S.
• Settled litigation in May 2025, receiving a $1.9 million payment.
• Reduced workforce in April and July 2025 to cut costs as U.S. production increased.

What Makes Retractable Technologies Stand Out

The company’s automated retraction technology helps reduce accidental needle injuries for healthcare workers. Its flexible supply chain allows shifting production between the U.S. and abroad to manage tariffs and disruptions. Retractable Technologies holds exclusive rights to its core safety technology, supporting its position in the safety syringe market.

Five Things You Need to Know

• Q2 2025 net sales were $10,445,733, up 73.2% from Q2 2024.
• Domestic sales made up 81.3% of Q2 2025 revenue.
• Three customers accounted for 57.2% of Q2 2025 sales.
• Q2 2025 net loss was $87,471, improved from $14,164,640 loss in Q2 2024.
• Tariff expenses reached $561,000 in Q2 2025, impacting margins.

Bottom Line

Retractable Technologies has adapted to supply chain and tariff challenges by expanding U.S. production and cutting costs. The company remains focused on safety devices for healthcare, with a concentrated customer base and ongoing margin pressures.